Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAVAB: Bortezomib for Antibody-Mediated Autoimmune Diseases
2013-005362-19Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Dec 2013
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in myasthenia gravis (MG) and autoantibody mediated diseases, sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Change in disease-specific autoantibody titers. Started Dec 2013; status: terminated.
02
Drugs
bortezomib
03
Conditions
myasthenia gravis (MG)autoantibody mediated diseases
Beyond the preview
Go deeper on 2013-005362-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005362-19.